

Jan S. Redfern, PhD

Strategic Medical Communications

Springtown, Texas • 845-772-2474 • jan@redfernstrategic.com • linkedin.com/in/jan-r-702a2a20 • ORCID: 0000-0002-3147-1089

CORE CAPABILITIES

- Clinical trial interpretation (Phases I–IV)
- Evidence hierarchy & statistical interpretation
- Scientific data visualization
- Publication strategy and lifecycle planning
- Manuscripts and systematic reviews
- Congress abstracts, posters / slide decks
- Plain language summaries
- Market research interpretation
- ICMJE & GPP publication standards
- Regulatory-compliant communications
- Veeva PromoMats • DataVision
- AI-enabled scientific communication

THERAPEUTIC EXPERTISE

- Cardiovascular disease and HF
- Respiratory medicine and asthma
- Allergy and immunology
- Gastrointestinal physiology
- Inflammatory disease mechanisms

GUIDELINE & RESEARCH EXPERIENCE

- GINA asthma guideline research
- AAAAI / ACAAI guideline interpretation
- ACC / AHA cardiovascular frameworks
- Survey-based clinical research design

EDUCATION

PhD, Physiology – University of Sheffield, United Kingdom

BSc (Hons), Physiology – University of Sheffield, United Kingdom

PUBLICATION RECORD

- 60 peer-reviewed academic publications
- >100 pharmaceutical-sponsored publications and scientific communications

EXECUTIVE PROFILE

Medical communications strategist and clinical research expert with more than 30 years of experience supporting pharmaceutical and biotechnology organizations across Phases I–IV development. Specialized in translating complex clinical evidence into high-impact scientific communications that support publication strategy, evidence dissemination, and regulatory-compliant medical messaging.

Recognized for rigorous interpretation of clinical evidence, development of guideline-aligned scientific narratives, and collaboration with regulatory, medical affairs, safety, legal, and commercial teams.

PROFESSIONAL EXPERIENCE

Owner & President | Redfern Strategic Communications | 1997–Present

- Lead strategic medical communications consultancy serving pharma and biotech
- Develop and implement publication development from concept through peer-reviewed journal submission
- Translate complex clinical and health-economic data into clear scientific communications
- Create manuscripts, congress presentations
- Ensure alignment with global publication ethics, authorship standards, and regulatory

Director, GI Physiology Laboratory | Baylor University Medical Center

Provided scientific leadership in clinical physiology research

Research Instructor → Research Assistant Professor | UT Southwestern Medical Center

Conducted clinical and basic research and contributed to peer-reviewed publications and grant development.

Therapeutic Experience

- Dermatology (plaque-type psoriasis, systemic sclerosis, fungal/bacterial/viral infections, onychomycosis, HPV, herpes zoster, leg ulcers)
 - Artificial skin (Apligraf), surgical devices (barbed sutures), posaconazole, terbinafine, infliximab
- Multiple sclerosis
 - Tecfidera (managed Tecfidera publication plan and developed journal articles/posters based on integrated summary of safety, including flushing, QoL, annualized relapse rate, disability progression, new/enlarging T2 hyperintense, nonenhancing T1 hypointense, and Gd+ lesions, and brain volume change)
 - Mavenclad, Rebif, evobrutinib (medical reviewer for promotional and scientific medical materials)
- Cardiovascular disease (hypertension, heart failure, LV hypertrophy, pre- and post-capillary pulmonary hypertension, ACS, atherosclerosis, dyslipidemia, MI, stroke, atrial fibrillation/ flutter)
 - ACE inhibitors, AIIAs, early activating K⁺ channels affecting atrial repolarization, and concentration-, voltage- and frequency-dependent blockade of Na⁺ channels, adenosine A1 receptor antagonists, fibrates, statins, niacin/laropiprant, CETP inhibitors (torcetrapib, anacetrapib), activin signaling inhibitor (sotatercept)
- Renal physiology and disease (ESRD, diabetic nephropathy, IgA nephropathy)
 - COX-2 inhibitors and renal function, ACE inhibitors, angiotensin II receptor blockers, targeted-release budesonide
- Cancer (neuroendocrine tumors, metastatic, triple-negative breast cancer, NSCLC [EGFR wild type and no EML4-ALK translocation], SCLC, melanoma/Merkel cell carcinoma, multiple myeloma, Hodgkin/non-Hodgkin lymphoma, B-cell lymphoma, solid tumors, head and neck tumors, gastric cancer, hepatocellular and kidney tumors, prostate and ovarian cancer [BRCA1 and BRCA2 mutations], cutaneous T cell lymphoma, urothelial cancer)
 - Chemotherapy (adjuvant and neoadjuvant), radiotherapy and immunotherapy (PD-1 antagonist alone or in combination), quavonlimab, lenvatinib, V937
 - HDAC inhibitors (vorinostat), CTCL-4 antibody (ipilimumab), PARP inhibitor (olaparib)
 - Theranostics (peptide receptor radiotherapy using ⁶⁸Ga-DOTATOC for imaging and ⁹⁰Y-DOTATOC for therapy)
 - Dual inhibitors of BCL-2/BCL-XL (pelcitoclax), BCL-2-selective inhibitor (lisaftoclax)
 - Breakpoint Cluster Region–Abelson (BCR-ABL) tyrosine kinase inhibitor (olverembatinib), activators of p53 tumor suppression via MDM2-p53 PPI (alrizomadlin)
 - BRAF inhibitor (vemurafenib) and MAPK signaling blocker (dabrafenib)
- CNS disorders (depression, psychosis, migraine, CNS degenerative disorders, appetite suppression, insomnia, attention deficit disorder, schizophrenia, Tourette's, schizophrenia, neuromyelitis optica)
 - Dual orexin receptor antagonists, risperidone, pimozide, modafinil, cholinesterase inhibitors, novel selective cannabinoid-1 receptor inverse agonists, 5-HT1B/1D agonist, asenapine
- Osteoporosis (post-menopausal and Paget's disease)
 - Alendronate
 - Odanacatib (cathepsin K inhibitor)

- Bleeding/coagulation disorders
 - Thromboprophylactic therapy, stem cells for therapeutic use, competitive PAR-1 antagonists, human coagulation factor FVIIa (recombinant)
- Vaccines
 - Multicomponent meningococcal serogroup B vaccine, pneumococcal conjugate vaccines, herpes zoster vaccine, influenza vaccine, quadrivalent and 9-valent HPV vaccine, MMR, ProQuad, Ebola (VSVΔG/ZEBOV-GP) vaccine, cytomegalovirus vaccine (V160), live attenuated measles virus-vectored Chikungunya virus vaccine, dengue fever (Dengue Quadrivalent Vaccine rDENVΔ30)
- Ocular disorders (glaucoma, macular degeneration, vacuolization)
 - VEGF-Trap-Eye, synthetic prostaglandin analogues (tafluprost), timolol
- GI diseases (diarrhea, constipation, GERD, ulcerative diseases, hepatitis C, GI pathophysiology, GI dysmotility)
 - Selective substance P (NK1–receptor) antagonist for chemotherapy-induced vomiting, serotonin 5-HT₄ receptor agonists, cisapride, HCV NS3 protease inhibitors, peg-interferon-alfa-2b, ribavirin
- Patient/physician surveys
 - Multiple pediatric vaccines, herpes zoster vaccine, hair loss, eczema, patient journey mapping, CVD/HFpEF, cholesterol management, absorption and production, eczema awareness and treatment in China
- Pharmacology
 - Single-dose and steady-state pharmacokinetics and pharmacodynamics, drug metabolism, drug-drug interaction
- Health policy
 - Bridging science and health policy in cardiovascular disease, nutrition (healthy food, health choices), obesity
- Pain (migraine, bone, dental, menstrual, postherpetic neuralgia, postorthopedic knee replacement, abdominal hysterectomy, arthritis, osteoporosis)
 - Etoricoxib, oxaprozin, rofecoxib, celecoxib, naproxen, rizatriptan, CGRP blockade, gefapixant (P2X₃ antagonist)
- Endocrinology (diabetes, acromegaly, infertility)
 - Corifollitropin-alfa for ovarian stimulation, selective DPP-IV inhibitors (sitagliptin and omarigliptin), insulin glargine, octreotide, glimepiride, metformin
- Infectious disease (*Clostridium difficile*-associated diarrhea, methicillin-resistant *Staphylococcus aureus*, complicated urinary tract infection, complicated intraabdominal infection, severe Gram-negative bacterial infections including IMI-resistant infection, nosocomial pneumonia (HABP, VABP, and healthcare-associated pneumonia), cytomegalovirus infection, hepatitis C, HIV/AIDS, SARS-CoV-2, respiratory syncytial virus (RSV)
 - Macrolide antibacterials, antipseudomonal cephalosporin, Class A/C β-lactamases, protein synthesis inhibitors with potent bactericidal gram-positive activity, CMV DNA terminase complex, HCV NS3 protease inhibitors, peg-INF-alfa-2b, ribavirin, efavirenz, NNRTIs, grazoprevir and elbasvir, doravirine/islatravir, molnupiravir, CD24Fc, bezlotoxumab, RSV monoclonal antibody (clesrovimab)
- Surgery (rocuronium- or vecuronium-induced neuromuscular blockade)
 - Reversal with sugammadex, neostigmine
- Respiratory disorders (asthma, allergic rhinitis, respiratory distress, rhinoconjunctivitis with or without asthma, refractory chronic cough, idiopathic pulmonary fibrosis)

- Ragweed (*Ambrosia artemisiifolia*) sublingual tablet, mometasone furoate/formoterol fumarate, montelukast, lung surfactant, antitussive (P2X3 and P2X2/3 receptor antagonist), soluble guanylate cyclase stimulator

Employment

Redfern Strategic Medical Communications, Inc., Springtown, TX

Owner/President, 1997-Present

- Develop, design, and produce all aspects of medical/scientific communications programs spanning a wide variety of health care audiences across all therapeutic categories
- Served as the subject matter expert and medical/scientific reviewer of promotional and non-product-related scientific/medical materials to ensure balance, accuracy and integrity of content, data, tables/graphs and references and to validate regulatory compliance
- Analyzes, translates, and presents market research data to support clinical development decision making
- Provides superlative standard of writing/editing, knowledge of research methods, and expertise in data analysis, interpretation, and presentation
- Medical/scientific reviewer of promotional and non-product-related scientific/medical materials to ensure accuracy and integrity of content, data, tables/graphs and references balance, regulatory compliance
- Deliver advanced understanding and clinical knowledge of the disease state, scientific evidence, clinical data, clinical trial methodology, outcomes, and limitations
- Write protocols, IRB submissions, and patient informed consent forms

Department of Life Sciences, Weatherford College, Weatherford, TX

Adjunct Faculty, 2018-2019

- Lecture and supervise laboratory classes on basic chemistry, biochemistry, histology, microscopy, gross anatomy and physiology to student nurses and students of other healthcare disciplines (e.g., respiratory therapists, occupational therapists)

Department of Pharmacotherapy, University of North Texas System College of Pharmacy, Fort Worth, TX

Adjunct Assistant Professor, 2017-2020

- Teach PharmD students select components of LGBT healthcare elective course
- Lectured on the basic tenets of evidence-based medicine, including the components of the hierarchical pyramid of clinical evidence, with a focus on the design and analysis of randomized clinical trials; also reviewed the foundations of meta-analyses and systematic reviews
- Presented practical overview of important measures of effect typically used in health studies, including absolute risk, absolute risk reduction, relative risk, relative risk reduction, odds ratio, hazard ratio, and number needed to treat; also reviewed the use and misuse of these methods with examples of how these measures should be correctly interpreted and reported

Complete Medical Communications, Hackensack, NJ (part-time position)

VP, Scientific Director (2013-2014)

Brought in by friend to rescue and expand a multiple sclerosis account—successfully accomplished

- Scientific input, supervision, and development of publication plan based on ongoing and completed clinical studies, interfacing with client's clinical research team, publication planning manager, statisticians, legal and marketing departments
- Supervised writing (in-house and freelance writers/editors) of all journal articles, abstracts, posters, presentations, field rep backgrounders and memos
-

Grey Healthcare Group/ Phase Five Communications, Inc., NYC

Senior Vice President, Director of Scientific Services 1995-1997

- Supervised 15 MD/PhD and editorial staff
- Interfaced with PR and advertising divisions of Grey
- Developed and expanded scientific services department and SOPs
- Contributed to new business proposals, spearheaded product development
- Ensured medical communications and education programs met the rigorous and exacting scientific scrutiny of leading scientists, clinicians, regulatory organizations, and pharmaceutical clients

Excerpta Medica, Reed-Elsevier Medical Group, Belle Mead, NJ

Director of Publications Programming 1994-1995

- Formulated and executed pharma publication strategies for domestic and international pharmaceutical clients

Project House, Inc., Hackensack, NJ

Medical/Scientific Director 1990-1994

- Researched, developed, and wrote medical/scientific communications projects
- Contributed to new business proposals and product development, presented scientific rationale at pitches, supported client services department

University of Texas Southwestern Medical Center at Dallas

Assistant Professor, Department of Internal Medicine 1988-1990

Research Instructor, Department of Internal Medicine 1984-1988

- Directed a vigorous research program investigating GI ulcerative diseases
- Supervised development, implementation, and SOPs for all analytical and preclinical techniques
- Published key findings in scientific/clinical journals and presented results at national and international scientific meetings
- Provided scientific direction and writing support for grant applications

Baylor University Medical Center, Dallas, TX

Research Fellow, Director GI Physiology Laboratory, 1982-1984

- Developed and supervised laboratory diagnostic procedures relating to malabsorptive syndromes, diarrhea, motility disorders, and fecal incontinence

Research Fellowships

1982-84	Research Fellow Baylor University Medical Center, Dallas
1981-82	Research Fellow University of Sheffield, England
1977-80	Science Research Council (Great Britain) Scholarship for Training in Research Methods (PhD program)

Education

PhD physiology (1977—81)	University of Sheffield, England Thesis: Neural and Humoral Regulation of Intestinal Ion Transport Processes
BSc (Hons) physiology (1974—1977)	University of Sheffield, England

Past/Present Society Membership/Editorial Experience

- International Society of Medical Publication Professionals
- Abstract selection committee and co-chairperson of scientific sessions on mucosal growth, damage, and repair, American Gastroenterological Association (1989-90)
- Ad hoc reviewer (1982-90) for articles submitted to Gastroenterology, American Journal of Physiology, and Prostaglandins
- American Heart Association
- American Diabetes Association
- New York Academy of Sciences
- American Medical Writers' Association
- Healthcare Businesswomen's Association
- International Law Enforcement Educators and Trainers Association

What Colleagues Say

- “It has been a special pleasure to collaborate closely with Jan as a coauthor in composing and writing a comprehensive, critical review of 25 years of literature in the area of pharmacotherapy for dyslipidemia, atherosclerosis, and associated cardiovascular disease. Throughout the process, Jan’s dedication to the project was outstanding, as was her ability to collate, interpret, and express the key findings in a manner that is understandable to a wide audience in this field. I cannot emphasize

sufficiently my appreciation of Jan's attention to detail at all stages of the development of the text, not the least of which concerned the demanding tabulation of extensive clinical trial data. Jan must be congratulated on all aspects of her exceptional contributions to the review, which went far beyond those of a medical editor and writer. Quite simply, Jan is at the peak in her profession, and I have no hesitation in highly recommending her superb editorial skills in the biomedical field to colleagues near and far."

John Chapman, Ph.D., D.Sc., FESC. President, European Atherosclerosis Society; Director, Dyslipidemia, Inflammation and Atherosclerosis Research Unit, National Institute for Health and Medical Research, Paris, France

- "...thorough, insightful, and extremely helpful throughout."

Prof. David Bates, Harvard Medical School, Boston, MA

- "Dr Redfern has an impressive ability to reduce complex medical information into a logical and clear stream of thoughts. She is highly skilled in organizing research data in a manner that will allow a comprehensive understanding of the subject and possesses unusual skills in terms of writing and clear presentation of the material. I can attest without any reservations that Dr. Redfern's writing skills are superb."

Prof. Carlos Ferrario, Bowman Gray-Wake Forest University Medical Center, Winston-Salem, NC

- Dr. Redfern is a superb medical writer. She possesses a sophisticated knowledge of medicine, highly developed writing skills and experience, the ability to interpret complex technical information and report it clearly. Moreover, Dr. Redfern is a highly professional and cooperative team member. It is a pleasure to work with her."

Leni Grossman (ret.), Director of Publications, Merck & Co., Inc., Whitehouse Station, NJ

- "Working with Dr. Jan Redfern on two research projects was absolutely delightful. She is an exceptionally talented and thoughtful writer and editor, with a diligent eye for details as well as an amazing understanding of the big picture. She is a savvy scientist and conscientious collaborator who greatly enhanced the process and products of my publications. Without a doubt, Jan's the best!"

Prof. Thomas Cash, Old Dominion University, Norfolk, VA

- "...highly skilled as a medical journalist, producing excellent reviews of scientific meetings."

Dr. Gordon McInnes, University Department of Medicine and Therapeutics, University of Glasgow, Glasgow, UK

- "Dr. Redfern's input was thorough but was done in a fashion that brought clarity to the area in which we were working; at the end, we had a scholarly review that advanced the knowledge in the field."

Prof. D. Craig Brater, Indiana School of Medicine, Indianapolis, IN

- "Dr. Redfern is a gifted medical writer, who approaches her subjects with care, is attentive to detail, and seeks to communicate in a balanced and accurate fashion."

Prof. Michael Alderman, Albert Einstein College of Medicine, Bronx, NY

- "I very much appreciate the excellent job you have done and the very professional manner with which you did it. Your help has been invaluable."

Denis O. Rodgerson, PhD, Director of Stem Cell Science, Founder NeoStem, Inc. New York, NY.

Personal Publications

Wang S, Tian J, Liang Y, Bissonnette R, Luger T, Koh M, Yu JD, Irvine AD, Yuval YR, **Redfern JS**, and Ma L. Real-world management of atopic dermatitis patients by healthcare professionals in Mainland China: An International Eczema Council Survey. *Intl J Dermatol* (submitted)

Gkini MA, Nakamura M, Alexis AF, Londoño-Garcia A, van de Kerkhof PCM, Doss N, Griffiths CEM, Kaufman B, Kleyn CE, Lebwohl M, **Redfern JS**, Takeshita J, Rajagopalan M, El Sayed MH. Psoriasis in people with skin of color—an evidence-based update. *Intl J Derm* 2025;64:667-677.

Redfern, JS. Role of regulatory T cells in the pathogenesis and therapeutics of neuromyelitis optica spectrum disorder. Chapter 12, in *Regulatory T Cells and Autoimmune Diseases*, Eds. Mitesh Kumar Dwivedi, DeLisa Fairweather. ISBN: 978-0-443-13947-5. Copyright 2024 Elsevier Inc

Redfern, JS. Immunopathophysiologic basis of multiple sclerosis and implications for therapy—a narrative review. *Pharm Pharmacol Int J*. 2021;9(6):263–271.

Redfern, JS. Theranostics: Cancer imaging and therapy using injectable radionuclide-labeled ligands. *Pharm Pharmacol Int J*. 2020;8(6):325–331.

Redfern, JS, Jann M. The evolving role of the pharmacist in healthcare. *Transgender Health* 2019; 4:1–13, DOI:10.1089/trgh.2018.0038.

De la Cruz C, Carvalho A, Leon-Dorantes G, Garcia AL, Gonzalez C, Maskin M, Podoswa N, **Redfern JS**, Valenzuela F, Van Der Walt J, Romiti R. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America. *J Dermatol* 2017;44(1):3-12.

Redfern JS, Barnes A, Chang J. Psychosocial, HIV, and health care management issues impacting transgender individuals. Invited review. *Am J Orthopsychiatry* 2016; 86(4): 366-372.

Redfern JS. Initiative to improve police interaction with transgender individuals. *International Law Enforcement Educators and Trainers Association Journal*. 2015; 5(2):18-19.

Redfern JS, Sinclair B. Improving health care encounters and communication with transgender patients. *J Comm Healthcare: Strategies, Media and Engagement in Global Health* 2014;7:25-40.

Redfern, JS. Nationwide survey of attitudes of law enforcement personnel towards transgender individuals (key findings). *Behavioral Health* 2014; 1(1): 1-2. Available at <http://www.jghcs.info/index.php/bh/article/view/318/283>.

Redfern JS. Nationwide survey of attitudes of law enforcement personnel towards transgender individuals. *J Law Enforcement.* 2014;4(1):1-24. Available at <http://jghcs.info/index.php//article/view/313>

Redfern JS. Best practices to improve police relations with transgender individuals. Training and Education section. *J Law Enforcement.* 2014;3(4):1-17. Available at <http://jghcs.info/index.php//article/view/265>

Chapman MJ, **Redfern JS**, McGovern ME, Giral P. Optimizing pharmacotherapy to combat the atherogenic lipid triad. *Curr Opin Cardiol* 2011;26:403-411.

Redfern JS, Thompson D. The risks and hazards of interpreting and reporting health study measures. A simple, practical overview. *AMWA J*, 2011; 26 (3):111-117 (featured article: science series). Full text available at <http://redfernstrategic.com/?p=88>.

Redfern JS, Quinn LF. Prescription for publication. How to submit patient or physician attitudinal survey data to medical journals. *Quirk's Market Research Review* 2011 (March):31-35 (cover story).

Chapman MJ, **Redfern JS**, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce residual cardiovascular risk. *Pharmacol Ther* 2010;126:314-345 (one of top 15 pharmacology articles downloaded from Science Direct for that year).

Alderman MH, **Redfern JS.** Serum uric acid—a cardiovascular risk factor? *Ther Umsch.* 2004;61(9):547-52.

Alderman M, **Redfern JS.** Uric acid: role in cardiovascular disease and effects of losartan. *Curr Med Res Opin.* 2004;20(3):369-79.

Gottesdiener K, Agrawal N, Porras A, Wong P, Rogers JD, Gertz BJ, **Redfern JS**, Marbury T. Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib. *Am J Ther.* 2003 Jul-Aug;10(4):252-8.

Schwartz JI, Vandormael K, Malice MP, Kalyani R, Lasseter KC, Holmes GB, Holmes GB, Gertz BJ, Gottesdiener K, Laurenzi M, **Redfern JS.** Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. *Clin Pharm Ther* 2002;72:50-61.

Schwartz JI, Agrawal NG, Wong PH, Bachmann KA, Porras AG, Miller JL, Ebel DL, Sack MR, Holmes GB, **Redfern JS**, Gertz BJ. Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. *J Clin Pharmacol.* 2001;41:1120-30.

Brater DC, Harris C, **Redfern JS**, Gertz B. Renal effects of COX-2 inhibitors. *Am J Nephrology* 2001;21:1-15.

Redfern JS, Fortuner WJ II. Octreotide-associated biliary tract dysfunction and cholesterol gallstone formation: pathophysiology and management. *Am J Gastroenterol.* 1995;90:1042-1052.

Harris AG, O'Dorisio TM, Woltering E, Anthony LB, Burton FR, Geller RB, Grendell JH, Levin B, **Redfern JS.** Consensus statement: Octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. *Dig Dis Sci.* 1995;40:1464-1473.

Harris AG, **Redfern JS**. Octreotide treatment of carcinoid tumors: analysis of published dose-titration data. *Aliment Pharm Therap*. 1995;9(4):387-94.

Redfern JS, O'Dorisio TM. Gastrointestinal hormones and carcinoid syndrome. In: Felig P, Baxter JD, Frohman LA, Eds. *Endocrinology and Metabolism*. 3rd Ed. New York, NY: McGraw-Hill; 1995;chap 27:1675-1701.

Redfern JS, O'Dorisio TM. Therapeutic uses of gastrointestinal peptides. *Endocrinol Metab Clin North Am*. 1993;22(4):845-873.

Cryer B, **Redfern JS**, Goldschmiedt MD, Lee E, Feldman M. Effect of aging on gastric and duodenal mucosal prostaglandin concentrations in humans. *Gastroenterology*. 1992;102:1118-1123.

Cryer B, Faust TW, Goldschmiedt MD, **Redfern JS**, Lee E, Feldman M. Gastric and duodenal mucosal prostaglandin concentrations in gastric or duodenal ulcer disease: relationships with demographics, environmental, and histological factors, including *Helicobacter pylori*. *Am J Gastroenterol*. 1992;87:1747-1754.

Redfern JS, Feldman M. Small intestinal permeability in prostaglandin-immunized rabbits with enteric ulcers. In: Tsuchiya M, Nagura H, Hibi T, Moro I, Eds. *Frontiers in Mucosal Immunology*. Amsterdam: Elsevier Science Publishers; 1991;2:589-592.

Redfern JS, Lin HJ, McArthur KE, Prince MD, Feldman M. Gastric acid and pepsin hypersecretion in conscious rabbits. *Am J Physiol*. 1991;261:G295-304.

Goldschmiedt M, Barnett CC, Schwartz BE, Karnes WE, **Redfern JS**, Feldman M. Effect of age on gastric acid secretion and serum gastrin concentrations in healthy men and women. *Gastroenterology*. 1991;101:977-90.

Goldschmiedt M, **Redfern JS**, Feldman M. Effect of propranolol on secretin-induced gastrin release and secretin-induced tachycardia in patients with the Zollinger-Ellison syndrome. *Aliment Pharmacol Ther*. 1990;4:325-31.

Cryer B, Goldschmiedt M, **Redfern JS**, Feldman M. Comparison of salsalate and aspirin on mucosal injury and gastroduodenal prostaglandins. *Gastroenterology*. 1990;99:1616-1621.

Faust TW, **Redfern JS**, Podolsky I, Grundy SM, Feldman M. Effects of aspirin on gastric mucosal prostaglandin E₂ and F_{2α} content and on gastric mucosal injury in humans receiving fish oil or olive oil. *Gastroenterology*. 1990;98:586-591.

Goldschmiedt M, **Redfern JS**, Feldman M. Food coloring and monosodium glutamate: effects on the cephalic phase of gastric acid secretion and gastrin release in humans. *Am J Clin Nutr*. 1990;51:794-797.

O'Dorisio TM, **Redfern JS**. Somatostatin and somatostatin-like peptides: clinical research and clinical applications. In: Mazzaferri YB, Ed. *Advances in Endocrinology*. St Louis, MO: Mosby Year Book; 1990;1:153-206.

Redfern JS, Mekhjian HS, O'Dorisio TM. Use of somatostatin-like peptides in the treatment of diarrhea. In: Bebenthal E, Duffey M, Ed. *Textbook of Secretory Diarrhea*. New York, NY: Raven Press;1990:chap 31.

Redfern JS, Feldman M. Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins. *Gastroenterology*. 1989;96:596-605.

Redfern JS, Lee E, Feldman M. Effect of immunization with prostaglandin metabolites on gastrointestinal ulceration. *Am J Physiol*. 1988;255:G723-G730.

Faust TW, **Redfern JS**, Lee E, Feldman M. Effect of dietary fish oil on ethanol-induced gastric mucosal injury in rats. *Am J Physiol*. 1989;257:G9-G13.

Faust TW, Lee E, **Redfern JS**, Feldman M. Effect of prostaglandin F_{3α} on gastric mucosal injury by ethanol in rats: comparison with prostaglandin F_{2α}. *Prostaglandins*. 1989;37:483-504.

Redfern JS. Prostaglandin synthesis and catabolism in the gastric mucosa. Studies in normal rabbits and rabbits immunized with PGE₂. *Prostaglandins*. 1988;36:355-372.

Heylings JR, **Redfern JS**, Feldman M. Inhibitory effect of isoproterenol on gastric acid secretion in the rat. Role of endogenous histamine. *Alimentary Pharmacol Therap*. 1988;2:419-428.

Redfern JS, Feldman M. About mechanism(s) of indomethacin gastric damage. *Gastroenterology*. 1987;93:1150.

Redfern JS, Lee E, Feldman M. Effect of indomethacin on gastric mucosal prostaglandins in humans. Correlation with mucosal damage. *Gastroenterology*. 1987;92:969-977.

Redfern JS, Blair AJ, Lee E, Feldman M. Gastrointestinal ulcer formation in rabbits immunized with prostaglandin E₂. *Gastroenterology*. 1987;93:744-752.

Redfern JS, Blair AJ, Lee E, Feldman M. Gastroduodenal ulceration following active immunization with PGE₂ in dogs. Role of gastric acid secretion. *Prostaglandins*. 1987;34:623-632.

Redfern JS, Feldman M. Lack of specific binding of prostaglandin E₂, prostaglandin F_{2α}, and 6-keto-prostaglandin F_{1α} to serum in patients with peptic ulcer disease and in healthy subjects. *Gastroenterology*. 1986;91: 71-74.

Redfern JS, Thirlby RC, Feldman M, Richardson CT. Effect of pentagastrin on gastric mucosal histamine in dogs. *Am J Physiol*. 1985; 248:G369-G375.

Jargis HA, Blackburn NA, **Redfern JS**, Read NW. The effect of ispaghula (Fybogel and Metamucil) and guar gum on glucose tolerance in man. *Br J Nutr*. 1984;51:371-378.

Blackburn NA, **Redfern JS**, Jarjis H, Holgate AM, Hanning I, Scarpello JHB, Johnson IT, Read NW. The mechanism of action of guar gum in improving glucose tolerance in man. *Clin Sci*. 1984;66:329-336.

Hardcastle J, Hardcastle PT, **Redfern JS**. Morphine has no direct effect on PGE₂-stimulated cyclic AMP production by rat isolated enterocyte. *J Pharm Pharmacol*. 1982;34:68.

Hardcastle J, Hardcastle PT, Read NW, **Redfern JS**. Effects of loperamide on prostaglandin E₂-induced secretion by rat small intestine. *Clin Res Rev*. 1981;1 (Suppl 1):148-156.

Hardcastle J, Hardcastle PT, **Redfern JS**. Action of 5-hydroxy tryptamine on intestinal ion transport in the rat. *J Physiol (Lond)*. 1981;320:41-55.

Browning JG, Hardcastle J, Hardcastle PT, **Redfern JS**. Localization of the effect of acetylcholine in regulating intestinal ion transport. *J Physiol (Lond)*. 1978;281:15-27.

Hardcastle J, Hardcastle PT, **Redfern JS**. The effect of prostacyclin on intestinal ion transport in the rat. *Life Science*. 1980;26:123-131.

Abstracts

De la Cruz C, Carvalho A, Leon-Dorantes G, Garcia AL, Gonzalez C, Maskin M, Podoswa N, **Redfern JS**, Valenzuela F, Van Der Walt J, Romiti R. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America. Abstract 1156. Psoriasis International Network, Paris, July 7-9, 2016.

Harris AG, **Redfern JS**. Octreotide treatment of carcinoid tumors: analysis of published dose-titration data. Presented at the *10th International Symposium on Gastrointestinal Hormones*, Santa Barbara, California, August 27 to 31, 1994.

Cryer B, **Redfern JS**, Lee E, Feldman M. Decline in gastroduodenal mucosal prostaglandins (PGs) with aging in humans. *Gastroenterology*. 1991;100:A518.

Cryer B, Faust T, Goldschmiedt M, **Redfern JS**, Lee E, Feldman M. Factors affecting gastroduodenal prostaglandins in healthy humans. *Clin Res*. 1991;39:A185.

Cryer B, Faust T, Goldschmiedt M, **Redfern JS**, Lee E, Feldman M. Mucosal prostaglandins (PGs) in peptic ulcer disease (PUD): correlation with demographic and histologic parameters. *Gastroenterology*. 1991;100:A49.

Redfern JS, Feldman M. Intestinal permeability in prostaglandin- immunized rabbits. Presented in person at a symposium entitled Mucosal Cytoprotection in the GI Tract, 6th *International Congress of Mucosal Immunology*, Tokyo, Japan, 1990;A321.

Redfern JS, Feldman M. Basal acid hypersecretion (BAH) in conscious, chronic gastric fistula rabbits. (Poster presentation at the American Gastroenterological Association, San Antonio, Texas, May, 1990) *Gastroenterology*. 1990;98:A111.

Goldschmiedt M, **Redfern JS**, Feldman M. Effect of propranolol on secretin-induced gastrin release and tachycardia in patients with the Zollinger-Ellison syndrome. *Gastroenterology*. 1990;98:A50.

Goldschmiedt M, **Redfern JS**, Barnett C, Schwartz B, Feldman M. Effect of age on gastric acid secretion and serum gastrin concentrations in healthy men and women. *Gastroenterology*. 1990;98:A50.

Faust TW, **Redfern JS**, Podolsky I, Feldman M. Effects of aspirin on gastric mucosal prostaglandin content and gastric mucosal injury in humans receiving fish oil or olive oil. *Gastroenterology*. 1989;96:147.

Redfern JS. Production of experimental ulcers by active and passive immunization against prostaglandin E2. Presented in person at a symposium entitled Is Peptic Ulcer a Prostaglandin-Deficiency Disease? Role of Synthetic Prostaglandins in Therapy, Asian Pacific Congress of Gastroenterology, Seoul, Korea, 1988.

Redfern JS, Feldman M. Antibody to 6-keto prostaglandin F1 α induces gastrointestinal ulceration in rabbits by binding to prostacyclin (PGI₂). (Presented in person at the American Gastroenterological Association meeting, New Orleans, May 16) *Gastroenterology*. 1988;94:371.

Faust TW, **Redfern JS**, Lee E, Feldman M. Dietary fish oil protects against ethanol-induced gastric mucosal injury in rats. *Gastroenterology*. 1988;94:123.

Faust TW, **Redfern JS**, Lee E, Feldman M. A comparison of gastric mucosal protection by prostaglandin F2 α and F3 α in rats challenged with absolute ethanol. *Gastroenterology*. 1988;94:123.

Redfern JS, Blair AJ, Lee E, Feldman M. Immunization with prostaglandins induces gastrointestinal (GI) ulcers in rabbits. (Presented in person at the American Gastroenterological Association meeting, Chicago, Ill, May 11) *Gastroenterology*. 1987;92:1591.

Redfern JS, Lee E, Feldman M. Induction of acute gastric ulcers in rabbits by passive transfer of PGE₂-hyperimmune plasma. (Presented in person at the Plenary Session of the American Gastroenterological Association meeting, Chicago, Ill, May 10) *Gastroenterology*. 1987;92:1591.

Hardcastle J, Hardcastle PT, Read NW, **Redfern JS**. The effect of loperamide on intestinal secretion. *Gastroenterol Clin Biol*. 1981;5:110.

Hardcastle J, Hardcastle PT, **Redfern JS**. The effect of 5-hydroxytryptamine on the electrical activity of intestinal mucosa. Presented in person to the Physiology Society of Great Britain, Plymouth, November, 1978 *J Physiol (Lond)*. 1979;287:24P-25P.

Redfern JS, Atkins D, Hardcastle J, Hardcastle PT. Effect of prostacyclin (PGI₂) on small intestinal cyclic AMP production in vitro. *Clin Sci Mol Med*. 1978;55:25P.

Browning JG, Hardcastle J, Hardcastle PT, **Redfern JS**. Site of action of acetylcholine in regulating intestinal ion transport in the rat. *J Physiol (Lond)*. 1977;270:78-79P.

Presentations at Symposia/Postgraduate Courses

Redfern JS. Transgender health. Presented at the Southcentral AIDS Education and Training Center, Parkland Health and Hospital System, Dallas, TX, April 3 2018. Audio/slide presentation available at <http://aidseducation.org/wpcontent/uploads/2018/05/Transgender%20Health%20recording-20180507%201503-1.mp4>

Redfern JS. Psychosocial issues impacting transgender women. Presented at the South Central AIDS Education and Training Center Program 13th Women and HIV International Clinical Conference, June 10, 2017, San Antonio, TX.

Redfern JS. Encompassing the Marginalized: Understanding Transgender Patients. Women's Health Enrichment Elective, University of Texas Southwestern Medical Center, Dallas, TX, October 14, 2015.

Redfern JS. Improving Police Interactions with Transgender Individuals. Presented at the *International Law Enforcement Educators and Trainers Association* meeting, Chicago, IL, April 21-24, 2015.

Redfern JS. Understanding Transgender and Gender Non-Conforming Individuals. Presented at the New York State Society for Clinical Social Work (Rockland Chapter), St Thomas Aquinas College, Sparkill, NY. April 12, 2015.

Redfern JS, Sinclair, B. Best Practices to Accommodate Trans Persons in a Binary Health Care System. Presented at the *Trans*Literate Conference: Emerging Clinical Concepts*. Sponsored by Psychotherapy Center for Gender and Sexuality (Division of Institute for Contemporary Psychotherapy), Hunter College, and LGBT Social Science and Public Policy Center. March 30, 2014, New York City, NY.

Redfern JS. Behavioral Health Encounters and Communication with Transgender Clients. CME workshop held at *CANDLE (Community Awareness Network for a Drug-free Life and Environment) Youth Pride Initiative, 4th Annual Professional Development Mini-Conference* for Youth-Serving Professionals interested in increasing their cultural competence for working with LGBTQ Youth. Held in conjunction with the Common Threads Youth Empowerment Retreat. January 18, 2014, Stony Point, NY

Redfern JS. Improving Sensitivity and Communication with Transgender Patients in Health Care Settings. Hudson River Health Care System, Haverstraw, NY, December 12, 2013.

Redfern JS, Hernandez-Goley E. VCS Inc Training and Professional Roundtable special presentation: Improving Sensitivity and Communication with Transgender Patients in Health Care Settings. Good Samaritan Hospital, Suffern, NY, October 9, 2013.

Redfern JS. Implementing effective publication strategies. Presented at seminar program entitled: Navigating the Pre-Marketing Period: the Pivotal Point for Successful Market Conditioning, sponsored by the Healthcare Businesswomen's Association, February 5, 1997.

Redfern JS, Feldman M. Intestinal permeability in prostaglandin- immunized rabbits. Presented in person at a symposium entitled Mucosal Cytoprotection in the GI Tract, *6th International Congress of Mucosal Immunology*, Tokyo, Japan, 1990.

Redfern JS. Endogenous prostaglandins and gastrointestinal mucosal ulceration. Presented in person at the bi-annual *Tennoji Topic Forum*, Osaka City University Medical School, Osaka, Japan, 1990.

Redfern JS. Production of experimental ulcers by active and passive immunization against prostaglandin E₂. Presented in person at a symposium entitled "Is Peptic Ulcer a

Prostaglandin-Deficiency Disease?" Role of Synthetic Prostaglandins in Therapy, Asian Pacific Congress of Gastroenterology, Seoul, Korea, 1988.

Redfern JS. Induction of gastrointestinal ulcers in rabbits by immunization with prostaglandin E₂. Presented in person at a minisymposium entitled Gut Mucosal, Cellular, and Molecular Biology, organized by the Center for Ulcer Research and Education (CURE), UCLA, 1987.

Redfern JS, Feldman M. Gastric mucosal defense. a cytoprotective role for prostaglandins? Presented at a post-graduate course in Clinical Gastroenterology and Endoscopy, San Antonio, Texas, September, 1985, sponsored by the American Gastroenterological Association and American Society for Gastrointestinal Endoscopy, 1985.

Feldman M, **Redfern JS.** Non-steroidal anti-inflammatory drugs, prostaglandins, and the gastric mucosa. Presented as part of the Annual Post-graduate Gastroenterology Course: An Intensive Review of Gastroenterology and Hepatology, Miami Beach, Florida, sponsored by American College of Gastroenterology, 1985.